Dinaciclib inhibits the stemness of two subtypes of human breast cancer cells by targeting the FoxM1 and Hedgehog signaling pathway. Tsao AN, Chuang YS, Lin YC, Su Y, et al. Oncol Rep 2022;47.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tsao AN, Chuang YS, Lin YC, Su Y, et al. Dinaciclib inhibits the stemness of two subtypes of human breast cancer cells by targeting the FoxM1 and Hedgehog signaling pathway. Oncol Rep 2022;47.
PMID: 35417031